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Abstract
Background: Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in persons
with HIV and also in children of 6–18 months of age in the developing world. To date, only nitazoxanide is licensed
for treatment of cryptosporidiosis, and only in persons after the first year of life and with healthy immune systems.
Clofazimine (CFZ: Lamprene®), an established drug that has been used for leprosy for more than 50 years, recently
has been described as effective against Cryptosporidium in vitro and in mouse infections. The efficacy and
pharmacokinetics of CFZ in vivo, in HIV-infected patients with cryptosporidial diarrhea are not known.
Methods: CRYPTOFAZ includes a randomized, double-blind, placebo-controlled study of the safety, tolerability and
Cryptosporidium inhibitory activity of orally administered CFZ in subjects with HIV infection and chronic diarrhea
with Cryptosporidium. An additional open label aspect of the study will compare the pharmacokinetics (PK) of
orally administered CFZ in HIV-infected individuals with and without Cryptosporidium-associated diarrhea. The
study will recruit a total of 66 subjects. Study participants will be given either CFZ or a placebo for 5 days while in
hospital and will be followed up after discharge. Cryptosporidium will be diagnosed by quantitative PCR as the
definitive test and by stool ELISA, which will also be used to quantify the shedding of Cryptosporidium in stool. PK
will be studied on plasma and stool samples. Primary endpoints include reduction in the number of
Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in
plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last
dose.
Discussion: This study provides an opportunity to explore a possible treatment option for HIV-infected patients
with cryptosporidial diarrhea, who, as of now in Malawi and most of sub-Saharan Africa, do not have a definitive
treatment apart from supportive care. The strength of this study lies in it being a randomized, double-blind,
placebo-controlled trial. If shown to be effective and safe, the findings will also lay a foundation for a future study
of the use of CFZ in children 6–18 months of age.
Trial registration: ClinicalTrials.gov, NCT03341767. Registered on 14 November 2017.
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Background
Cryptosporidium infection and diarrhea (cryptosporidi-
osis) is a life-threatening infection in persons with HIV
and also in children 6–18 months of age in the developing
world [1, 2]. Two main species of Cryptosporidium cause
infections in humans; Cryptosporidium hominis, causing
the majority of the infections, and Cryptosporidium par-
vum causing 20–30% of the infections [2]. To date, only
nitazoxanide is licensed for treatment of cryptosporidiosis,
and only in persons after the first year of life and with
healthy immune systems. A randomized trial in mal-
nourished children that were hospitalized with crypto-
sporidiosis and diarrhea showed only 30% efficacy of
nitazoxanide versus placebo in the treatment of crypto-
sporidiosis in HIV seronegative, but not seropositive
children [3]. It is not licensed for use in HIV-infected
and immunocompromised patients. One study claimed
benefits of using nitazoxanide in HIV-infected adult pa-
tients with CD4+ cell counts greater than 50 cells/μL
by administering high doses of the drug [4]. In studies
examining mortality as the endpoint, nitazoxanide has
not shown any benefits in HIV-infected and immuno-
compromised patients with cryptosporidiosis compared
to placebo [3, 5, 6].
Recently, an old drug, clofazimine (CFZ, sold under
the brand name Lamprene®) has been described as ef-
fective against Cryptosporidium in vitro, and has been
shown to eliminate C. parvum in a mouse model [7].
Clofazimine has been in use for more than 50 years for
treatment of leprosy, and remains on the World Health
Organization (WHO) essential drug list. Clofazimine is
also used as part of a WHO regimen to treat multi-drug
resistant Mycobacterium tuberculosis. The pharmacokin-
etics (PK) of CFZ administration have been reported
after a single dose and multiple dosing, but never in in-
dividuals with diarrhea or HIV infection.
Discovery of an effective drug for cryptosporidiosis that
is safe to use in HIV-infected patients with advanced im-
munosuppression and in children under 1 year of age will
benefit these groups of patients, who as of now do not
have any effective treatment options. This clinical trial will
evaluate the safety, tolerability, PK and efficacy of CFZ in
HIV-infected adults with cryptosporidiosis.
Methods/design
Study hypotheses
This study (Additional file 1) is divided into two parts.
The first part, part A, is a phase 2A study that assesses
safety, tolerability and anti-cryptosporidial activity of or-
ally administered CFZ. For part A, we hypothesize that
CFZ (Lamprene®) orally administered daily for 5 con-
secutive days, will be safe and well-tolerated and will sig-
nificantly reduce Cryptosporidium concentration in the
first collected stool of the day over a 5-day period, as
measured by quantitative PCR (qPCR) 18S rRNA spe-
cific to Cryptosporidium species. This will be tested by
analysis of covariance (ANCOVA) in comparison to
comparable placebo-treated HIV-infected controls with
chronic diarrhea and Cryptosporidium infection treated
according to protocol (ATP).
The second part, part B, is a phase 2A study of the PK
of orally administered CFZ (Lamprene®) in HIV-infected
adults without diarrhea or Cryptosporidium infection.
The PK of CFZ in blood and stool in this population will
be compared to those in the HIV-infected adults with
diarrhea and Cryptosporidium infection. For this part,
we hypothesize that the PK of CFZ will be similar in
HIV-infected adults with and without diarrhea and
Cryptosporidium infection.
Study objectives
The primary objectives for part A are to evaluate
whether there is a reduction in Cryptosporidium fecal
shedding following CFZ administration relative to pla-
cebo in HIV-infected adults with diarrhea and Crypto-
sporidium infection; and to investigate the safety and
tolerability of CFZ when orally administered daily for 5
consecutive days in this population. For part B, the ob-
jective is to investigate the PK of CFZ in HIV-infected
adults with Cryptosporidium infection and diarrhea
compared to the PK in HIV-infected subjects without
Cryptosporidium infection or diarrhea.
Study design
This is a two-part study. Part A is a randomized,
double-blind, placebo-controlled study of the safety, toler-
ability and Cryptosporidium inhibitory activity of orally
administered CFZ in subjects with HIV infection and
chronic diarrhea (for at least 3 days’ duration), with
Cryptosporidium infection demonstrated by stool testing.
Part B is an open label study, intended to compare the PK
of orally administered CFZ in HIV-infected individuals
with and without Cryptosporidium-associated diarrhea.
End points
Primary endpoints
The primary endpoints are:
1. Safety assessments collected throughout the follow
up period: adverse events (AEs), serious adverse
events (SAEs), vital signs, 12-lead electrocardiogram
(ECG), physical examinations (PE), and clinical la-
boratory evaluations.
2. The reduction in the (log) number of
Cryptosporidium shed in stools in the first collected
stool of the day over a 5-day period and compared
to placebo recipients, as measured by qPCR in stool
samples and analyzed by mixed-effect analysis of
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covariance (ANCOVA) in subjects treated ATP
(part A only).
3. Pharmacokinetics of CFZ in plasma: area under the
curve (AUC), peak plasma concentration (Cmax),
and time to reach Cmax (Tmax) on the second and
last dose days; half-life (T ½) determined after the
last dose.
4. The amount of CFZ in stool on day 2 (2nd dose
day), day 5 (last dose day), and day 6 (concentration
of CFZ in stool before discharge).
Secondary endpoints
The secondary endpoints are:
1. The reduction in the (log) number of
Cryptosporidium shed in stools in the first collected
stool of the day over a 5-day period and compared
to placebo recipients in the intention to treat (ITT)
subject population
2. The reduction in total daily Cryptosporidium
shedding over a 6-day period in subjects treated
ATP (part A only)
3. The reduction in total daily Cryptosporidium
shedding over a 6-day period in comparison to pla-
cebo controls in the ITT population
4. The reduction in severity of diarrhea over a 6-day
period in comparison to placebo controls in sub-
jects treated ATP
Study site
The study take place at Queen Elizabeth Central Hospital
(QECH) in Blantyre, Malawi. It is the main referral hos-
pital for the southern region in Malawi. There is an out-
patient Gateway Clinic close by the hospital, that screens
and either manages or refers outpatients, who may be
self-referred or referred from primary Health Centers, be-
fore they are seen at the tertiary hospital; some additional
subjects will be recruited from the Gateway Clinic.
Sample size
The sample size for part A was planned based on the
goal that demonstration of a significant inhibition of
Cryptosporidium shedding should be possible in a rela-
tively small number of subjects, if the drug is to be
worth further development efforts. Based on results in a
calf model with a controlled challenge, the sample size
required would be very small (e.g. 10 per group) if the
variability of shedding in the study population planned
for enrollment in this study is small. Since the variability
in shedding in the planned study population cannot be
estimated, a study size of 25 per group (increased to 28
per group to cover dropouts) was planned in case
variability is more substantial than expected. An interim
analysis is planned after 20 subjects have been
randomized and successfully completed the study drug
administration phase of the study. An analysis of the
primary efficacy endpoint is planned at that time for
success. If success is determined, the study will be termi-
nated. If success is not determined, an analysis for futil-
ity of continuation will be performed. If the study
appears to be adequately powered to achieve significance
of the primary efficacy endpoint based on that analysis,
it will be continued until full enrollment and follow up.
The second part of this study is empirical, and will in-
clude approximately the first 10 CFZ recipients in part
A and a new set of 10 recipients without diarrhea or
Cryptosporidium infection who will be recruited specif-
ically for part B. Pharmacology of CFZ will be compared
in the individuals receiving CFZ in part A with those in-
dividuals receiving CFZ in part B. The objective is to de-
velop a comparative description of the absorption and
excretion of the drug in the HIV-positive populations
with and without Cryptosporidium-associated diarrhea.
Inclusion/exclusion criteria
Part A
Inclusion criteria The subjects to be included will be
male or female, aged 18–65 years old, HIV-positive,
Cryptosporidium positive by qPCR, and on stable anti-
retroviral (ARV) treatment for at least 2 weeks. They
should weigh more than 35.4 kg and should have chronic
diarrhea (defined as a condition of three or more loose
stools per day that has persisted for 3 days or longer). If
female, they should not be of reproductive potential
(post-menopause, or status-post surgical sterilization) or
be using, or be willing to use, highly effective contracep-
tion (< 1% failure, e.g., intrauterine contraceptive device or
injectable contraception). They should be willing and able
to provide signed written informed consent (IC) or wit-
nessed documented oral consent in the case of illiteracy,
prior to undertaking any trial-related procedures.
Exclusion criteria The exclusion criteria are:
 Any condition for which participation in the study,
as judged by the investigator, could compromise the
wellbeing of the subject or prevent, limit or
confound protocol-specified assessments.
 Fever > 38.0 °C on presentation.
 Evidence of active tuberculosis based on acid fast
bacilli staining or GeneXpert testing of sputum or
sputum production, fever, and chest x-ray consistent
with tuberculosis.
 Critical illness, or in the judgment of the
investigator a prognosis that could lead to imminent
mortality within 60 days, compromise participation
Nachipo et al. Trials  (2018) 19:456 Page 3 of 11
in the trial, or endanger the subject by entering the
trial
 History of allergy or hypersensitivity to CFZ
 Significant cardiac arrhythmia requiring medication
 ECG exclusions based on the means from triplicate
ECGs performed on day 1:
 Marked prolongation of the QT/QTc interval, e.g.,
confirmed demonstration of QTcF or QTcB
interval > 450 ms
 Pathological Q waves (defined as > 40 ms or depth >
0.4 mV);
 ECG evidence of ventricular pre-excitation
 ECG evidence of complete or incomplete left bundle
branch block or right bundle branch block
 ECG evidence of second-degree or third-degree
heart block
 Intraventricular conduction delay with QRS
duration > 120 ms
 Bradycardia as defined by sinus rate < 50 bpm
 History of additional risk factors for Torsade de
Pointes, e.g., heart failure; bradycardia with heart
rate (HR) < 50 bpm, untreated hypothyroidism,
hypokalemia < 3.2 mEq/L
 Family history of long QT syndrome
 Use of concomitant medications that markedly
prolong the QT/QTc interval or are predicted to have
drug-drug interactions with CFZ that may lead to tox-
icity from the partner drug, including amiodarone,
amprenavir, atazanavir, bedaquiline, bepridil, chloro-
quine, chlorpromazine, cisapride, clarithromycin,
cyclobenzaprine, darunavir, delamanid, disopyramide
dofetilide, domperidone, droperidol, erythromycin,
fosamprenavir, halofantrine, haloperidol, ibutilide, in-
dinavir, levomethadyl, lopinavir, mesoridazine, metha-
done, nelfinavir, pentamidine, pimozide,
procainamide, quinidine, ritonavir, simiprinivir, sotalol,
sparfloxacin, thioridazine, or tiprinivir
 Pregnant and lactating women
 Use of systemic corticosteroids or anti-cryptosporidial
treatments within the preceding 28 days
 Clinically significant laboratory value abnormalities
at screening including but not limited to (note:
exclusionary results may not be returned until after
enrollment but should be confirmed by the time of
the beginning of administration of study drug):
 Hemoglobin < 5 g/dL
 Serum potassium < 3.0 mEq/L
 Aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) ≥ 3.0 times the upper limit
of normal (ULN)
Part B
Patients presenting to the HIV or other outpatient
clinics at QECH who do not have diarrhea will be
offered the opportunity to participate. Subjects will be
selected on the basis of matching (demographic) criteria
compared to the first 10 subjects weighing > 50 kg who
are enrolled and administered the investigational prod-
uct (IP) (with either CFZ or placebo) in part A, i.e.,
based on similar age (± 5 years), gender, and stage of
HIV infection according to the WHO criteria. Subjects
enrolled in part B will need to weigh > 50 kg. Otherwise,
except for the absence of diarrhea and Cryptosporidium
infection, the eligibility and exclusion criteria will be the
same as for subjects enrolled in part A.
Study phases
There will be three phases in the study: screening (pre-
screening and screening) and inpatient and outpatient
phases.
Screening phases
The screening phase of the study will include the pre-
screening and screening phases (Fig. 1). In the prescre-
ening phase, stool is tested for the presence of
Cryptosporidium. Consent to participate in the screen-
ing and study phases will be obtained after prescreening.
After documented informed consent (IC) and enroll-
ment in part A or part B, subjects will be screened for
additional eligibility and exclusion criteria. Those sub-
jects who are eligible for the treatment phases of part A
or part B will continue in the study. The prescreening
and screening phases for parts A and B are expected to
last from 1 to 5 days.
Study phase: inpatient
Subjects participating in parts A and B will be moni-
tored daily during the inpatient phase of the study via
examination by a study clinician, solicitation of daily
progress reports, monitoring of gastrointestinal (GI),
dermatological, and systemic signs and symptoms,
reviewing medical conditions, and noting adverse
events (AE). Vital signs will be recorded three times
daily, and more often, based on the clinician’s judg-
ment. If a subject develops GI symptoms or other ex-
pected AEs that cause them to desire discontinuation
of treatment, IP administration will be discontinued
and the reasons for discontinuation recorded. Blood
and stool samples will be collected according to proto-
col. All stools will be collected in disposable plastic
containers for weighing and grading of the stool
consistency. The volume will be calculated from the
weight, assuming 1 g = 1 mL. For part A, stools will be
graded for presence and severity of diarrhea.
Study phase: outpatient (parts A and B)
Subjects will be asked to return to the outpatient clinic
for one outpatient follow up visit during the interval
Nachipo et al. Trials  (2018) 19:456 Page 4 of 11
days 19–24, and one outpatient follow up visit during
the interval days 41–55. They will be questioned about
the occurrence of any symptoms reflecting expected AEs
associated with CFZ treatment and any other interven-
ing illnesses, and blood and stool samples will be col-
lected as per protocol.
Study treatments, dose, and mode of administration
Part A
This part is to assess the safety and tolerability of CFZ
when administered to subjects with HIV infection and
diarrhea with positive stool test for Cryptosporidium,
and the potential inhibitory effect of CFZ treatment on
shedding of Cryptosporidium in stool. There will be an
initial screening phase and a study phase. For the initial
screening phase, subjects presenting with chronic diar-
rhea and a history of HIV infection with ARV treatment
for at least a month will be asked to volunteer to be
tested for the presence of Cryptosporidium infection as
a screening test for potential participation in the treat-
ment phase. After providing documented IC, subjects
will be screened. Subjects testing positive for Crypto-
sporidium infection will be asked to volunteer for the
treatment phase of the study. After consenting to par-
ticipate for the treatment phase, full eligibility for par-
ticipation in this phase will be determined.
The complete screening process including prescreen-
ing and screening for part A will take 1–5 days. Fully eli-
gible subjects will be admitted to the clinical research
ward. Subjects who do not meet all eligibility criteria will
be informed of their results and referred for any treat-
ment required, as appropriate. The day of admission to
the clinical research ward will be day 1. Subjects will be
randomized to the IP and administration of the IP will
begin on day 1. Assessments will continue daily during
the inpatient phase. The inpatient phase will include IP
administration on days 1–5.
On day 6, assessments will be performed and the sub-
jects will be discharged for outpatient follow-up. Sub-
jects will be asked to return to the outpatient clinic for
one outpatient follow up visit during the interval days
19–24, and one outpatient follow up visit during the
interval days 41–55 unless additional follow up is
needed until resolution of ongoing AEs or completion of
unexpected pregnancy.
The active IP will be administered orally as 50-mg gel-
atin capsules of micronized CFZ suspended in an
oil-wax base. Two capsules of either CFZ (100 mg) or
placebo will be given to subjects weighing 50 kg or more
and one capsule for those weighing less. Both the active
drug and the placebo are made and provided for this
study by Novartis. Study drug will be taken with food
and to achieve this uniformly, study subjects will be fed
with Plumpy’Soy or Plumpy’Nut nutritional supplement
30 min before each dose, and each dose will be given at
least 1.5 h before the next anticipated meal. The doses
will be administered at 5:00 a.m., 11:00 a.m., and
5:00 p.m. Accordingly, a total daily dose of 150 mg (body
weight < 50 kg) or 300 mg (body weight > 50 kg) will be
administered for 5 days. The IP dose was split to
minimize the probability of fecal excretion of intact
Lamprene gelatin capsules. If clinical research staff
members discover that a dose was not administered on
time, it will be administered immediately and the actual
time noted, and the subsequent dose should not be given
any sooner than 4 h after the “late” dose. A “missed/late”
Fig. 1 Schematic diagram for study enrollment and conduct. RDT, Cryptosporidium rapid diagnostic test; IP, investigational product;
PK, pharmacokinetics
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dose within an hour of the next dose, will be forgone
and the next scheduled dose administered as planned. If
a subject misses administration of the IP for ≥ 48 h,
treatment will be discontinued.
If a subject leaves the study ward before completion of
the scheduled study procedures on day 6, an effort will
be made to contact the subject at his/her home to
complete CFZ dosing and specimen collection. Subjects
who fail to complete the study will be included in the
ITT analyses, and any PK data obtained will be included
in the PK analyses. If a subject does not return for follow
up, efforts will be made to locate the subject to complete
the study as an outpatient.
Part B
This part is to compare the PK of orally administered CFZ
in HIV-infected individuals with and without Cryptospori-
dium-associated diarrhea and will include individuals in
part A who received CFZ and 10 subjects without diar-
rhea. The 10 subjects in part B will be recruited from the
HIV and other outpatient clinics and will not be random-
ized. They will provide IC and be screened for the pres-
ence of Cryptosporidium. If negative, they will provide
documented IC, and will be admitted to the Clinical In-
patient Unit. They will receive the active IP, with a dosing
schedule similar to part A participants. Since subjects will
be admitted specifically for the purpose of this study, com-
pletely missed doses are not anticipated. Should a subject
discontinue participation before the 4th day of CFZ ad-
ministration, an additional subject will be recruited. All of
the pharmacodynamic data obtained for both the dropout
and replacement subjects will be included in data analyses.
Screening, randomization, and masking procedures
Screening
Part A
Patients who meet the inclusion criteria will be asked to
consent to participate in a study that involves initial
screening for the presence of Cryptosporidium. After a
subject provides consent, a stool sample will be collected
and subjected to Cryptosporidium rapid diagnostic test
(RDT) and qPCR. It is anticipated that the results of the
RDT and qPCR will be available within 8 h and 36 h, re-
spectively. Subjects who are positive by RDT will be of-
fered the opportunity to participate in part A. Subjects
who were RDT positive but qPCR negative will be in-
formed of the results and that they will not be eligible to
continue in part A. Subjects who were RDT negative but
are found to be qPCR positive will be offered the oppor-
tunity to participate in part A.
Part B
Screening for participation in part B will follow the same
process as for participation in part A, except that
subjects will be offered the opportunity to participate
only if they do not have diarrhea, and stool screening
tests (RDT and qPCR) are negative for infection with
Cryptosporidium.
Enrollment and randomization
Subject randomization will occur at the time of initiation
of treatment. An unblinded pharmacist will be provided
with the treatment assignment codes for preparation of
the CFZ or placebo to be given to each subject. A desig-
nated individual at the site, i.e. the research pharmacist,
will be provided with a code list for emergency unblind-
ing purposes, which will be kept in a secure place.
Laboratory evaluations
Clinical laboratory evaluation
Stool samples will be collected from the subjects en-
rolled in the study and the following tests will be
conducted:
 Cryptosporidium ELISA test (TechLabs Inc.)
 Cryptosporidium DNA by qPCR analysis
 Baseline stool sample DNA will be preserved for
later GI TaqMan Array analysis
 Cryptosporidium genotyping for species and subtype
 Cryptosporidium oocysts from day 1 will be
evaluated for sensitivity of the individuals’
Cryptosporidium isolate to CFZ in vitro
The rest of the investigations to be done and their
schedules are summarized in Fig. 2.
Research laboratory evaluations
Pharmacology evaluations will be performed as follows:
A. Plasma samples for PK analysis
Plasma samples will be collected from the first 20 sub-
jects treated ATP in part A and for the 10 subjects in
part B:
 Days 1 and 5 (1st day and last day of dosing): PK
plasma samples will be collected prior to study drug
administration:
 Pre-dose: 0 h
 Post-dose 1: 2 h (± 12 min), 3 h (± 18 min) and
4 h (± 24 min)
 Pre-dose 2: immediately before the second dose (or
skip if within 30 min of the previous sample ~ 4 h)
 Pre-dose 3: 12 (up to 16) h post 1st dose
 Day 2 and 3 (2nd and 3rd days of dosing): PK
plasma samples will be collected prior to study drug
administration
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Study Event
Study Day/Interval
Inpatient 
or
Outpatient
Screening1
Inpatient
Day
Two 
Outpatient
Visits
-1 1 2 3 4 5 6 19-24 41-55
Informed Consent for prescreening X
Brief Medical History for HIV treatmentX
Stool for Cryptosporidium RDT and 
qPCR
X
Informed Consent for PART A or B X
Inclusion/Exclusion Criteria X
Urine Pregnancy Test X X2 X
Sputum for Acid Fast and GeneXpert X
Chest X-ray X
12-lead ECG in Triplicate X X X
12-lead ECG X X X3
Blood for CD4 count and HIV viral 
load
X
Vital Signs X X X4 X4 X4 X4 X4 X X X
Physical Exam X X X X
Medical History X X X X
Abbreviated Physical Exam X X4 X4 X4 X4 X4
Medical Interview, Verbal Review of 
Systems, Concomitant Medications 
Review, and Probing for Solicited 
AEs
X4 X4 X4 X4 X4
Safety Labs - Hematology X5.6 X5 X5 X6
Safety Labs -Clinical Chemistry X5,6 X5 X5 X6
Stool for GI TaqMan Array and
Genotype (enrolled subjects only)
X
Randomization X
IP Administration – 3 doses per day X X X X X
1st Collected stool of the day 
for Cryptosporidium ELISA
X7 X X X X8 X X
1st Collected stool of the day 
Stool for Cryptosporidium qPCR
X X X X X X X8 X X
~q8 hr stool pool 
for Cryptosporidium qPCR9
X9 X9 X9 X9 X9 X9
~q8 hr stool for weighing and grading9 X9 X9 X9 X9 X9 X9
Stool(s) for CFZ concentration10 X10 X12 X12 X8, 11 X11 X11
Plasma for CFZ concentration10 X X X X X8 X X
1Entire process from prescreen consent to randomization on Day 1 will take from 1 to 5 days.
2Pregnancy test for women of child bearing potential.
3ECG will be done at last patient visit if abnormal or changing at previous visit
4Prior to each dose of IP, which is to be given at least 1.5 hrs before the next expected meal.
5Safety Labs: Complete blood count, Na, K, Cl, HCO3, Cr, BUN, Glucose, AST, ALT, and Alk Phos.
6Repeat labs if required to resolve abnormal values.
7A sample of this stool will be retained for MIC50 testing.
8Samples will be collected in the morning of Day 6 prior to discharge from Clinical Inpatient Unit; full 24 hr of stool samples 
not collected.
9Samples will be collected and pooled.
10Samples will be collected from all PART B subjects and only on the first 20 randomized PART A subjects treated according 
to protocol, then a subset of plasma samples (on Days 1, 5 and 6) will be collected on the final randomized subjects (see 
protocol section 7.4.3).
11Only first collected stool sample of the day measured for CFZ.
12Samples from each ~q8h stool collection measured for CFZ on Day 2 and Day 5.
Total blood volume to be obtained from the first 20 subjects in PART A treated ATP and subjects in PART B will be 
approximately 108 ml, and for remaining subjects in PART A will be approximately 48 ml, including all testing described 
here and elsewhere in this protocol.
Fig. 2 Summary of study events schedule. RDT, Cryptosporidium rapid diagnostic test; ECG, electrocardiogram; AEs, adverse events; GI,
gastrointestinal; IP, investigational product; ELISA, enzyme-linked immunosorbent assay; CFZ, clofazimine; BUN, blood urea nitrogen; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; Alk Phos, alkaline phosphatase
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 Day 6: PK plasma samples will be collected at
approximately the time of discharge and the time
noted
After discharge, the plasma PK samples will be col-
lected on both follow up visits.
The following samples will be collected for the final
diarrheic (part A) subjects, after the first 20 diarrheic
subjects are enrolled and treated according to protocol.
 Day 1: 0 h (pre-dose), 4 h (± 24 min) post 1st dose
 Day 5: pre-dose 3, immediately before the third
dose, and 4 h (± 24 min) post dose 3
 Day 6: just prior to discharge (note time post final dose)
B. Stool samples for PK analysis
Stool samples for PK endpoints will be collected from
the first 20 part-A subjects and all part-B subjects. A stool
sample for baseline CFZ levels will be collected before
dosing on day 1 (first inpatient day). Total stool collection
roughly every 8 hours (~ q8 h measured, scored, mixed,
and sampled) will be undertaken during the days of in-
patient stays throughout the study. These stools will be
pooled. Stool will be collected on days 2 and 5 for meas-
urement of CFZ levels. On day 6 the morning stool will be
collected for CFZ determination prior to discharge. Sub-
jects will be asked to return to the outpatient clinic for
one outpatient follow up visit during the interval days 19–
24, and one outpatient follow up visit during the interval
days 41–55. The subject will be asked to bring morning
stool samples with them in containers provided for qPCR
Cryptosporidium excretion and CFZ levels.
Statistical considerations
Analysis plan
All continuous variables will be summarized using the fol-
lowing descriptive statistics: number (analysis population
size) (N), number (non-missing sample size) (n), mean,
standard deviation (SD), median, interquartile range
(IQR), maximum and minimum. Note that the geometric
mean will also be reported in descriptive summary tables
for log-transformed variables. The proportion of observed
levels will be reported for all categorical measures. When
appropriate, corresponding exact 95% confidence intervals
(CIs) for proportions will be included.
In general, all data will be listed, sorted by study de-
sign (part A and part B) and by subjects. When appro-
priate, data will also be presented by study day within
study design and subject. All summary tables will be
structured with a column for each treatment in the
order (CFZ, placebo) for part A and a column for part B.
If applicable, a column for the part A subjects that were
matched to part B subjects will also be provided.
The primary analysis will be based on the ATP popula-
tion. Safety analyses will be based on the safety popula-
tion and all PK analyses will be based on the PK
population. Analysis populations are defined below.
Analysis populations
This study will have three analysis populations: the ITT
population, the population that was treated ATP, and the
PK population. The ITT population will consist of all
randomized subjects. The ATP population will consist of
all subjects in the ITT population who meet the follow-
ing criteria: received at least one dose per day for 5 days,
completed daily assessments of fecal shedding, and had
no major protocol deviations. The PK population will
consist of all ITT subjects who had at least one measur-
able PK concentration.
Safety analysis (part A)
Cumulatively, the CFZ safety database represents more
than 2 million patient-years of exposure. Toxicities seen
with CFZ are most commonly observed after weeks to
months of use and include skin color change (reddish/
brownish) and GI symptoms (abdominal pain, constipa-
tion, with accumulation of CFZ in the GI tract). In a
study recently conducted of CFZ treatment in tubercu-
losis (drug regimen 300 mg per day for 3 days followed
by 100 mg/day for the remainder of 2 weeks), 3/60 pa-
tients on CFZ-containing regimens developed some skin
discoloration while 0/45 patients on non-CFZ regimens
experienced skin discoloration (D. Herman, personal
communication). Rarely, hepatobiliary disorders, such as
hepatitis and associated liver function test abnormalities
have been reported. Some short-term GI intolerance has
also been reported, but can usually be managed symp-
tomatically without suspending administration of the
drug. No hematological or biochemical blood abnormal-
ities have been associated with CFZ use.
All safety analyses will be based on the ITT population
and will be presented by treatment group. The baseline
value for all subjects will be the assessment made on day
1 in the Clinical Inpatient Unit. ECG results, vital signs,
laboratory parameters, and physical examination abnor-
malities will be presented in list format.
Efficacy analysis (part A)
The primary efficacy endpoint in the present trial is the
change from baseline in the (log) number of Cryptospor-
idium shed (in terms of number of oocysts shed per
gram) in the first stool collected each day over a 5-day
inpatient period, as measured by qPCR in treatment ver-
sus placebo. The primary analysis will be performed
based on the ATP population. A mixed ANCOVA model
for repeated measures will be used to model and analyze
the difference between treatment groups, in the change
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from baseline in the log-transformed number of oocysts
shed per gram in the first individual stool collected via
qPCR each day over the 5-day inpatient period, starting
with day 2. The model will include terms for gender,
age, HIV stage of infection, the baseline log number of
Cryptosporidium shed, day, and treatment group. Ex-
ploratory analyses will comprise linear regression models
to consider the effects of various factors on reductions
in fecal shedding, including age, sex, body weight, drug
exposure, baseline oocyst shedding, parasite genotype,
time on ARV treatment, CD4 count, viral load, and indi-
vidual 50% minimum inhibitory concentration (MIC50).
Interim analysis
A detailed description of the interim analysis plan will be
included in the statistical analysis plan (SAP) that will be
completed before the interim analysis. After approximately
20 subjects have completed the study ATP, an interim ana-
lysis of the primary efficacy endpoint and for futility will
be performed. Alpha for the interim and final analyses will
be apportioned using a power family alpha spending func-
tion with a phi value of 0.58. This alpha-spending function
apportions approximately alpha = 0.03 one-sided for both
the interim and final analysis, assuming an information
fraction of 40%. At the time of the interim analysis the
confidence interval (CI) for the difference in mean oocyst
reductions over the treatment period (log2 CFZ – log2
placebo) will be determined using ANCOVA. If the upper
limit of the CI is less than − 1, then the trial will be
stopped early for success. If the lower limit exceeds − 1,
then the trial will be stopped early for futility.
Final analysis
Due to the interim analysis, the primary and secondary
efficacy analyses will be conducted using an alpha level
of 0.03 for determination of significance in a one-sided
comparison. Although the test of significance will be
conducted at alpha level of 0.03, the overall type I error
will be 0.05 one-sided which will be used for the infer-
ence of primary and secondary efficacy outcomes.
Secondary analyses
A Cox proportional hazards regression model will be
used to evaluate whether the time to first negative fecal
ELISA signal is decreased in subjects randomized to
CFZ. ANCOVA will be used to assess the reduction in
the number of diarrheal episodes and the (log) number
of Cryptosporidium shed in stools in the first collected
stool of the day over a 5-day period (days 2–6).
Pharmacokinetic analysis (part B)
All PK analyses will be based on the PK population.
Non-compartmental PK analysis will be undertaken to de-
rive relevant PK parameters (e.g., AUC 0–24, AUC 0–8,
Cmax, Cmin for day 1 (1st dose day) and day 5 (last dose
day). Terminal half-life will be determined after the last
dose. PK parameters will be summarized using descriptive
statistics. Given the PK characteristics of CFZ, exposures
are expected to accumulate over the 5-day dosing period.
The accumulation ratio will be defined as AUC 16–24 on
day 5 divided by the AUC 0–8 on day 1. PK parameters in
symptomatic subjects will be compared to those in
matched asymptomatic subjects. The total daily amount
of CFZ eliminated in the feces will be calculated on the
second and last dose days. Stool PK parameters from
Cryptosporidium-positive subjects with diarrhea and
Cryptosporidium-negative subjects without diarrhea will
be compared.
Safety monitoring
The safety of the study will be monitored by the site
Principal Investigator (PI), the study Medical Monitors,
an independent Local Safety Monitor (LSM), and the
Data Safety Monitoring Board (DSMB). The LSM is an
experienced clinician independent of the investigator
team, but on the staff at QECH. The LSM will be noti-
fied within 24 h of the Site PI being aware of a SAE oc-
currence. A DSMB will be appointed to provide data
and safety oversight. The DSMB, consisting of a mini-
mum of three qualified members, will review all SAEs
and adverse events of special interest (AESI) as cumula-
tive reports at their scheduled meetings, or individually
on an ad hoc basis, requested by the Sponsor Medical
Monitor, the PI, or the LSM. The DSMB and the LSM
have the power to recommend holding or stopping of
the study to the Sponsor, if deemed necessary. Interim
analyses on unblinded data will be performed by the
DSMB after 20 subjects in part A have completed treat-
ment ATP. The DSMB will recommend to the Sponsor
whether to continue or terminate the study based on the
interim analyses. The Pharmacy, Medicines and Poisons
Board (PMPB) and the National Health Sciences
Research Committee will be notified within 24 h of
becoming aware of a SAE. All safety events observed
under this protocol will be reported through the Advan-
tage eClinicalSM data system. Subjects who experience
AEs that are ongoing at the time of the last scheduled
follow up visit will be followed to resolution or
stabilization. Subjects who are pregnant during the study
will be followed to completion of pregnancy.
Discussion
Human cryptosporidiosis is typically a self-limited infec-
tion, except in malnourished children under 2 years of
age and in seriously immunosuppressed patients, espe-
cially patients with HIV infection. Effective treatment of
HIV infection reduces the risk of severe cryptosporidi-
osis, but patients with severe disease may still experience
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severe manifestations from Cryptosporidium infection
that include wasting and death if immunosuppression
cannot be alleviated with ARVs.
CFZ is an anti-leprosy agent on the WHO Essential
Medicines list. It has been a Food and Drug Administra-
tion (FDA)-approved drug, although its distribution in the
USA is currently limited to specialized leprosy treatment
centers. CFZ is also used for treatment of multidrug resist-
ant tuberculosis. CFZ exerts a slow bactericidal effect on
Mycobacterium leprae by inhibiting mycobacterial growth,
possibly by binding preferentially to mycobacterial DNA.
It also exerts anti-inflammatory properties in controlling
erythema nodosum leprosum (ENL) reactions through
inhibition of plasma membrane K+ transporters, and
increased production of prostaglandin E2 and the
interleukin-1 (IL-1) receptor antagonist by immune,
inflammatory and other cell types [8, 9]. Other mecha-
nisms of CFZ antibacterial effect that have been proposed
include membrane-directed activity on the bacterial re-
spiratory chain and ion transporters, generation of
superoxide-hydrogen peroxide, and the antimicrobial lyso-
phospholipids, which promote membrane dysfunction,
resulting in interference with K+ uptake [10–12]. CFZ also
exerts its anti-mycobacterial action by its effect on the tis-
sue macrophages, which are the main targets of infection
as well as immune response in tuberculosis [13]. It is
taken up by macrophages throughout the body; in autop-
sies performed on leprosy patients, CFZ crystals have been
found predominantly in the mesenteric lymph nodes, ad-
renals, subcutaneous fat, liver, bile, gall bladder, spleen,
small intestine, muscles, bones, and skin.
This study investigates the safety, tolerability and effi-
cacy of orally administered CFZ in subjects with HIV in-
fection, chronic diarrhea, and Cryptosporidium
infection, and the PK of CFZ in HIV-infected adults with
and without Cryptosporidium infection and diarrhea.
CFZ has been shown to inhibit CYP3A4 in vitro, and
therefore has the potential to lead to drug-drug interac-
tions especially with certain antiretrovirals (ARVs) used
in HIV therapy, though not with the first-line current
ARV treatment used in Malawi in adults (currently teno-
fovir/lamivudine/efavirenz).
The strength of part A of this study lies in it being
a randomized, double-blind, placebo-controlled trial.
If shown to be effective and safe, findings will also
lay a foundation for a future study on the use of CFZ
in children 6–18 months of age. The trial is spon-
sored by the University of Washington and has been
approved by the Liverpool School of Tropical Medi-
cine and National Health Sciences Research Commit-
tee of Malawi (NHSRC). It will be conducted by the
Malawi-Liverpool-Wellcome Trust Clinical Research
Programme (MLW), in collaboration with the Univer-
sity of Washington and the Emmes Corporation.
There are some anticipated challenges in this study.
The study has strict exclusion criteria, which may make
recruitment of the subjects a challenge. We are planning
to recruit patients in the outpatient department of
QECH, the Gateway Clinic and in the wards. We hope
this will give sufficient numbers to enroll into the study.
It is anticipated that a few subjects may not remain in
the clinical inpatient unit for the planned duration of
the inpatient phase of the study. In these cases, an effort
will be made to continue IP administration and study as-
sessments on an outpatient basis. Subjects will be en-
couraged to return to the outpatient clinic for continued
participation ATP. If subjects refuse to come to the out-
patient clinic, an effort will be made to visit them in
their homes for follow-up with regard to safety. They
will be encouraged to return on day 6 for final ECG. An-
other challenge is that, in our experience and that of
others, multiple pathogens in addition to Cryptosporid-
ium are found in patients with HIV, Cryptosporidium in-
fection, and diarrhea. A potential anti-Cryptosporidium
drug, such as CFZ, may have no effect on the other
pathogens, and thus may not alleviate symptoms. Thus
we are measuring the reduction in cryptosporidium ex-
cretion as the primary outcome, and not cessation of
clinical symptoms, which is a secondary outcome.
Another challenge may be variability in excretion of
Cryptosporidium from day to day. Since subjects will be
on ARVs, there is a risk that they will self-cure. To our
knowledge, no previous study has tried to quantitate
Cryptosporidium excretion in the study population.
Thus, it remains to be seen whether a therapeutic effect
on Cryptosporidium excretion will be measureable.
In summary, this study provides an opportunity to ex-
plore a possible treatment option for HIV-infected pa-
tients with cryptosporidial diarrhea, who, as of now in
Malawi and most of sub-Saharan Africa, do not have a
definitive treatment apart from supportive care.
Trial status
This manuscript presents version 4.0 of the CRYPTO-
FAZ protocol. The trial opened for accrual in December
2017 and is expected to be completed by October 2018.
Additional file
Additional file 1: Standard protocol items: recommendation for
interventional trials (Spirit) checklist. (DOC 190 kb)
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